Replimune Group, Inc.
REPL
Rank in Stocks
#5742
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering... Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Share Price
$22.26
Last synced: 2026-11-09
Market Cap
$2.11B
Change (1 day)
2.96%
Change (1 year)
146.24%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Replimune Group, Inc. (REPL)
Category
Healthcare
P/B ratio for Replimune Group, Inc. (REPL)
P/B ratio as of November 2026 TTM: 9.04
According to Replimune Group, Inc.'s latest financial reports and stock price, its current price-to-book ratio (TTM) is 9.04. At the end of 2025 the company had a P/B ratio of 1.89.
P/B ratio history for Replimune Group, Inc. from 2017 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 9.04 | 378.56% |
| 2025 | 1.89 | 37.47% |
| 2024 | 1.37 | -25.79% |
| 2023 | 1.85 | -14.12% |
| 2022 | 2.16 | -23.80% |
| 2021 | 2.83 | 52.17% |
| 2020 | 1.86 | -28.72% |
| 2019 | 2.61 | -115.66% |
| 2018 | -16.66 | -41.17% |
| 2017 | -28.31 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 7.0081 | -22.52% |
US
|
|
| 12.9864 | 43.58% |
US
|
|
| 4.5726 | -49.44% |
AU
|
|
| 4.5877 | -49.28% |
BE
|
|
| 6.7286 | -25.61% |
NL
|
Questions about Replimune Group, Inc.'s P/B ratio
What is Replimune Group, Inc.'s P/B ratio?
Replimune Group, Inc.'s P/B ratio is 9.04, as of Nov 2026.
What was Replimune Group, Inc.'s P/B ratio in 2025?
In 2025, Replimune Group, Inc.'s P/B ratio was 1.89, compared with 1.37 in 2024.
How has Replimune Group, Inc.'s P/B ratio changed since 2020?
From 2020 to 2025, Replimune Group, Inc.'s P/B ratio was highest in 2021 (2.83) and lowest in 2024 (1.37).
How does Replimune Group, Inc.'s P/B ratio compare with similar companies?
Replimune Group, Inc.'s P/B ratio (9.04) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Moderna, Inc., with 12.99.